Justa thought to share for us long-term shareholders (and new shareholders alike) about the recent increase incommunication from management.
1.We did not have a fully subscribed shareholder placement.
2.DrHowie McKibbon spruiking Australian "investors are comfortable backing earlystage, high-risk biotechs" a couple of days ago.
3.Now the investorpresentation of the potential of SB and Revenues.
4.Is $8Min cash reserves enough to commercialise on the good news that we are about to be received / announced?
I amsuggesting for discussion that management are preparing the market for a capital raise forcommercialisation, given the good news of the FDA approval.
Watchingwith an open mind and has anyone else had this thought bubble?
Gilp
Ann: Webinar Updated Commercial Research for Sofpironium Bromide, page-7
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.020(6.25%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.8¢ | 33.5¢ | $1.464M | 4.319M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77586 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 292810 | 7 |
View Market Depth
| Last trade - 10.52am 14/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |